Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome
Sponsor: Neurocrine Biosciences
Terminated
Futility
Other terminated trials from Neurocrine Biosciences
Other Tourette Syndrome trials with similar outcome
A PHASE2 clinical study on Tourette Syndrome, this trial is terminated or withdrawn. The trial is conducted by Neurocrine Biosciences and has accumulated 16 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jun 2022 [monthly]
Terminated PHASE2
▶ Show 11 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Sep 2019 — Mar 2020 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
May 2019 — Sep 2019 [monthly]
Recruiting PHASE2
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE2
-
Dec 2018 — Apr 2019 [monthly]
Recruiting PHASE2
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE2
-
Jul 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
First recorded
Apr 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Neurocrine Biosciences
For direct contact, visit the study record on ClinicalTrials.gov .